Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 660 participants.

Also called NCT01462266

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 660 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01462266
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01462266. Randomized; double masking; primary purpose treatment. Start 2012-01-13 (actual); primary completion 2013-06-06 (actual). Results posted on 2014-04-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Comparator: Placebo
Intervention (Biological)
Insulin Glargine
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01462266
Content hash
6a763d476f59f192c15d2d89f781f3a6efea12fc8d0e673a7b36a5d1f2759952